[Controlled, double blind study of a possible interaction between acemetacin and a concomitant anticoagulant therapy].
In a controlled double blind study, 20 patients undergoing long-term anticoagulant therapy with phenprocoumon received [1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetoxy]acetic acid (acemetacin, TV 1322, Rantudil) concomitantly to establish whether there was any risk of an interaction. Neither the placebo dose nor the concomitant medication with 3 x 60 mg acemetacin had any statistically important influence on thromboplastin value, fibrinogen, phenprocoumon consumption or platelet aggregation. Accordingly, no clinically relevant interaction is to be expected by the concomitant therapy with 3 x 60 mg acemetacin/d and phenprocoumon, or in all probability, with any coumarin compound.
D015110:4-Hydroxycoumarins / Q000494:pharmacology*; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D004311:Double-Blind Method; D004347:Drug Interactions; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007210:Indoleacetic Acids / Q000494:pharmacology*; D007213:Indomethacin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000494:pharmacology* / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects; D013925:Thromboplastin / Q000378:metabolism
D015110:4-Hydroxycoumarins; D000893:Anti-Inflammatory Agents; D007210:Indoleacetic Acids; C026784:acemetacin; D005340:Fibrinogen; D013925:Thromboplastin; D010644:Phenprocoumon; D007213:Indomethacin
Kontrollierte Doppelblindstudie zur Frage einer möglichen Interferenz von Acemetacin mit einer laufenden Antikoagulanzien-Therapie.